 Conventional allogeneic hematopoietic cell transplantation HCT for patients with hematological malignancies involves conditioning with high doses of systemic chemoradiation therapy such as cyclophosphamide CY plus 1200 or 1000 cGy total body irradiation TBI; CYTBI or busulfan Bu CY BuCy. Unfortunately, such regimens have been associated with significant toxicities, limiting their use to otherwise healthy, relatively young patients. 